<DOC>
	<DOCNO>NCT00001111</DOCNO>
	<brief_summary>Monotherapy phase : To evaluate compare safety , tolerance , pharmacokinetics , preliminary activity nevirapine administer alone mildly moderately symptomatic HIV-infected child age 2 month le 18 year ; evaluate compare safety , tolerance , pharmacokinetics nevirapine HIV-infected child age 1 day less 2 month . Combination therapy phase : To evaluate compare safety , tolerance , pharmacokinetics , preliminary activity nevirapine administer combination zidovudine ( AZT ) mildly moderately symptomatic HIV-infected child age 2 month le 18 year . Compounds reverse transcriptase inhibitory activity potent less toxic nucleoside analogue need . Nevirapine ( BI-RG-587 ) show vitro inhibitory activity HIV-1reverse transcriptase show synergistic inhibition HIV-1 replication combine zidovudine ( AZT ) plaque reduction assay .</brief_summary>
	<brief_title>A Study Nevirapine Used Alone Combination With AZT HIV-1-Infected Children</brief_title>
	<detailed_description>Compounds reverse transcriptase inhibitory activity potent less toxic nucleoside analogue need . Nevirapine ( BI-RG-587 ) show vitro inhibitory activity HIV-1 reverse transcriptase show synergistic inhibition HIV-1 replication combine zidovudine ( AZT ) plaque reduction assay . Sixty mildly moderately symptomatic HIV-infected child ( five patient four age group ) receive oral nevirapine 1 3 dos 168 day . If preliminary activity demonstrate toxicity acceptable 84 day treatment three old age group ( age 2 month - less 2 year , age 2 year - less 13 year , age 13 year - less 18 year ) , child age 1 day - le 2 month receive one three dos nevirapine . Additionally , 15 additional patient ( five three age group ) receive zidovudine combination nevirapine . At end 24 week combination therapy , patient discontinue zidovudine 2 week remain nevirapine , order pharmacokinetic sample do . Children enrol sequentially decrease age increase nevirapine dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : IV gammaglobulin therapy . Medications PCP prophylaxis ( e.g. , TMP / SMX , dapsone , aerosolize IV pentamidine ) . Fluconazole . Patients must : HIV infection . A positive Polymerase Chain Reaction ( PCR ) acceptable sole evidence HIV infection . Three five child age dose group must serum p24 antigen level 70 pg/ml great and/or plasma viral titer 50 TCID/ml great prior study entry . Ability follow original trial center duration trial . Consent parent guardian . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Lymphocytic interstitial pneumonitis steroiddependent require supplemental oxygen pretreatment paO2 &lt; 70 mm Hg . Opportunistic serious bacterial infection within 28 day prior entry . Demonstrated intolerance zidovudine prior administration nevirapine ( patient enrol combination therapy phase study ) . CDC classification P2D ( secondary infectious disease ) and/or P2E ( secondary cancer ) . Preexisting malignancy . Concurrent Medication : Excluded : Other approve investigational antiretroviral agent . All investigational agent ( except fluconazole ) . Glucocorticoids steroid hormone . Dicumarol , warfarin , anticoagulant . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Isoniazid . Phenobarbital barbiturates . Hepatotoxic drug . Patients prior participation trial exclude . Prior Medication : Excluded : More 6 week prior zidovudine ( AZT ) therapy 6 week antiretroviral therapy . Excluded within 7 day prior study entry : AZT ( monotherapy group ) . Excluded within 4 week prior study entry : Other approve investigational antiretroviral agent . All investigational agent . Glucocorticoids steroid hormone . Dicumarol , warfarin , anticoagulant . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Isoniazid . Phenobarbital barbiturates . Active alcohol drug abuse impair compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>